JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2

Hepatology Research

Volumn 46, Issue 2, 2016, Pages 129-165

  Asahina, Yasuhiro ^a   Izumi, Namiki ^b   Hiromitsu, Kumada ^c   Kurosaki, Masayuki ^b   Koike, Kazuhiko ^d   Suzuki, Fumitaka ^c   Takikawa, Hajime ^e   Tanaka, Atsushi ^e   Tanaka, Eiji ^f   Tanaka, Yasuhito ^g   Tsubouchi, Hirohito ^h   Hayashi, Norio ⁱ   Hiramatsu, Naoki ^j   Yotsuyanagi, Hiroshi ^d  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^h Kagoshima City Hospital   (Japan)

ⁱ KANSAI ROSAI HOSPITAL   (Japan)

^j OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; DACLATASVIR; INTERFERON; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VANIPREVIR;

ARTICLE; CLINICAL DECISION MAKING; HEALTH CARE PERSONNEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; MEDICAL SOCIETY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION;

EID: 84958595297     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12645     Document Type: Article

References (96)

1. Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. Hepatol Res 2013; 43: 1-34.
2. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1. Hepatol Res 2014; 44(Suppl S1): 59-70.
3. Choo QL, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
4. Kiyosawa K, Sodeyama T Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
5. Hagiwara H, Hayashi N, Mita E et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with IFN-alpha. Hepatology 1992; 15: 37-41.
6. Cardoso AC, Moucari R, Figueiredo-Mendes C et al. Impact of Peg-IFN and RBV therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-7.
7. Ikeda K, Saitoh S, Arase Y et al. Effect of IFN therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.
8. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after IFN treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394-402.
9. Yoshida H, Shiratori Y, Moriyama M et al. IFN therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by IFN Therapy. Ann Intern Med 1999; 131: 174-81.
10. Asahina Y, Tsuchiya K, Tamaki N et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52: 518-27.
11. Enokimura N, Shiraki K, Kawakita T et al. Hepatocellular carcinoma development in sustained viral responders to IFN therapy in patients with chronic hepatitis C. Anticancer Res 2003; 23: 593-6.
12. Iwasaki Y, Takaguchi K, Ikeda H et al. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to IFN therapy. Liver Int 2004; 24: 603-10.
13. Okanoue T, Itoh Y, Minami M et al. IFN therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30: 653-9.
14. Shindo M, Hamada K, Oda Y et al. Long-term follow-up study of sustained biochemical responders with IFN therapy. Hepatology 2001; 33: 1299-302.
15. Takimoto M, Ohkoshi S, Ichida T et al. IFN inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci 2002; 47: 170-6.
16. Tanaka H, Tsukuma H, Kasahara A et al. Effect of IFN therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000; 87: 741-9.
17. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha IFN. A preliminary report. N Engl J Med 1986; 315: 1575-8.
18. Hayashi N, Okanoue T, Tsubouchi H et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012; 19: e134-e42.
19. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and Peg-IFN with or without RBV for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
20. Kumada H, Toyota J, Okanoue T et al. Telaprevir with Peg-IFN and RBV for treatment-naïve patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
21. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with Peg-IFN and RBV for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
22. McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
23. Hayashi N, Izumi N, Kumada H et al. Simeprevir with Peg-IFN/RBV for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014; 61: 219-27.
24. Izumi N, Hayashi N, Kumada H et al. Once-daily simeprevir with Peg-IFN and RBV for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014; 49: 941-53.
25. Kumada H, Hayashi N, Izumi N et al. Simeprevir (TMC435) once daily with Peg-IFN-alpha-2b and RBV in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res 2014; Jun 24. doi:. DOI:10.1111/hepr.12375. [Epub ahead of print].
26. Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083-91.
27. Arase Y, Ikeda K, Suzuki F et al. Prolonged-IFN therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 2007; 79: 1095-102.
28. Izumi N, Asahina Y, Kurosaki M et al. Inhibition of hepatocellular carcinoma by Peg-IFNalpha-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. J Gastroenterol 2013; 48: 382-90.
29. George SL, Bacon BR, Brunt EM et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49: 729-38.
30. Morgan TR, Ghany MG, Kim HY et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.
31. Camma C, Di Marco V, Lo Iacono O et al. Long-term course of IFN-treated chronic hepatitis C. J Hepatol 1998; 28: 531-7.
32. Marcellin P, Boyer N, Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to IFN-alpha therapy. Ann Intern Med 1997; 127: 875-81.
33. Pradat P, Tillmann HL, Sauleda S et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 2007; 14: 556-63.
34. Reichard O, Glaumann H, Fryden A et al. Long-term follow-up of chronic hepatitis C patients with SVR to alpha-IFN. J Hepatol 1999; 30: 783-7.
35. Saracco G, Rosina F, Abate ML et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of IFN-alpha 2b. Hepatology 1993; 18: 1300-5.
36. Imai Y, Kawata S, Tamura S et al. Relation of IFN therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129: 94-9.
37. Gao M, Nettles RE, Belema M et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
38. McPhee F, Sheaffer AK, Friborg J et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012; 56: 5387-96.
39. Lok AS, Gardiner DF, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
40. Chayama K, Suzuki F, Suzuki Y et al. All-oral dual combination of daclatasvir plus asunaprevir compared with telaprevir plus Peg-IFN alfa/RBV in treatment-naïve Japanese patients chronically infected with HCV genotype 1b: results from a phase 3 study. Hepatology 2014; 60: 1135A.
41. DAKLINZA tablets interview form. Bristol-Myers K.K., 2014.
42. SUNVEPRA capsules interview form. Bristol-Myers K.K., 2014.
43. McPhee F, Friborg J, Levine S et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 2012; 56: 3670-81.
44. Fridell RA, Qiu D, Wang C et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54: 3641-50.
45. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26: 487-503.
46. Manns M, Pol S, Jacobson IM et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014. DOI:10.1016/S0140-6736(14)61059-X[Epub ahead of print].
47. Suzuki Y, Ikeda K, Suzuki F et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58: 655-62.
48. Fridell RA, Wang C, Sun JH et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54: 1924-35.
49. Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus RBV for hepatitis C. N Engl J Med 2013; 368: 34-44.
50. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for treatment-naïve chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
51. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
52. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and RBV in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
53. Omata M, Nishiguchi S, Ueno Y et al. Sofosbuvir plus RBV in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014; 21: 762-8.
54. Gilead. Antiviral drug SOVALDI tablets 400 mg package insert. 2015.
55. Lawitz EJ, Gruener D, Hill JM et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012; 57: 24-31.
56. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
57. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
58. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
59. Mizokami M, Yokosuka O, Takehara T et al. Ledipasvir and sofosbuvir fixed-dose combination with and without RBV for 12 weeks in treatment-naïve and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015; 15: 645-53.
60. HARVONI combination tablets interview form. Gilead, 2015.
61. Chayama K, Notsumata K, Kurosaki M et al. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 2015; 61: 1523-32.
62. Kumada H, Chayama K, Rodrigues L Jr et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015; 62: 1037-46.
63. VIEKIRAX combination tablets parkege insert. Abbvie, 2015.
64. VIEKIRAX combination tabletsinterview form. Abbvie, 2015.
65. Hayashi N, Seto C, Kato M et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2013; 49: 138-47.
66. Gane E, Hyland R, Yang Y et al. Ledipasvir/Sofosbuvir single tablet regimen is effective in patients with HCV genotype 2 infection. 15th International symposium on viral hepatitis and liver diseases (ISVHLD). Berlin, Germany 2015.
67. Jensen DM, Marcellin P, Freilich B et al. Re-treatment of patients with chronic hepatitis C who do not respond to Peg-IFN-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528-40.
68. Oze T, Hiramatsu N, Yakushijin T et al. Efficacy of re-treatment with Peg-ylated IFN plus RBV combination therapy for patients with chronic hepatitis C in Japan. J Gastroenterol 2011; 46: 1031-7.
69. Poynard T, Colombo M, Bruix J et al. PegIFN alfa-2b and RBV: effective in patients with hepatitis C who failed IFN alfa/RBV therapy. Gastroenterology 2009; 136: 1618-28 e2.
70. Ghany MG, Nelson DR, Strader DB et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54: 1433-44.
71. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364: 2417-28.
72. Pol S, Aerssens J, Zeuzem S et al. Similar SVR rates in IL28B CC, CT or TT prior relapser partial- or null-responder patients treated with telaprevir/Peg-IFN/RBV: retrospective analysis of the realize study. J Hepatol 2011; 54: S6-7.
73. Kumada H, Toyoda N, Goto K et al. The efficacy of Peg-interferon a-2b and ribavirin combination therapy for 24 weeks for patients infected with HCV genotype 1 and low viral load or genotype 2: comparison with interferon a-2b and ribavirin combination therapy for 24 weeks. Kan-tan-Sui. 2006; 52: 645-63. [in Japanese]
74. Inoue Y, Hiramatsu N, Oze T et al. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by Peg-ylated IFN alpha-2b and RBV: reducing drug doses has no impact on rapid and SVRs. J Viral Hepat 2010; 17: 336-44.
75. Irishio K, Imai Y, Mita E et al. A study of the efficacy of Peg-IFN alfa-2a monotherapy in serotype 2 chronic hepatitis C patients. Acta Hepatologica Japonica 2011; 52: 236-43.
76. Harada N, Hiramatsu N, Oze T et al. Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines. J Gastroenterol 2013; 48: 535-43.
77. Hiramatsu N, Inoue Y, Oze T et al. Efficacy of Peg-ylated IFN plus RBV combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study. J Gastroenterol 2011; 46: 1335-43.
78. Kainuma M, Furusyo N, Azuma K et al. Pegylated IFN alpha-2b plus RBV for Japanese chronic hepatitis C patients with normal alanine aminotransferase. Hepatol Res. 2012; 42: 33-41.
79. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975-82.
80. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358: 958-65.
81. Izumi N, Kaneko S, Nishiguchi S et al. A phase 2/3 study to investigate the efficacy and safety of Peg-IFN alfa-2a (40 KD)+RBV combination therapy in compensated cirrhosis type C. Gastroenterology 2011; 53: 335-42.
82. Reddy KR, Bourliere M, Sulkowski M et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology (Baltimore, Md) 2015; 62: 79-86.
83. Bourliere M, Bronowicki JP, de Ledinghen V et al. Ledipasvir-sofosbuvir with or without RBV to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15: 397-404.160.
84. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995; 346: 1051-5.
85. Lok AS, Everhart JE, Wright EC et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011; 140: 840-9.
86. Forman LM, Lewis JD, Berlin JA et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
87. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192-204.
88. Annicchiarico BE, Siciliano M, Avolio AW et al. Treatment of chronic hepatitis C virus infection with Peg-ylated IFN and RBV in cirrhotic patients awaiting liver transplantation. Transplant Proc 2008; 40: 1918-20.
89. Forns X, Garcia-Retortillo M, Serrano T et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-96.
90. Iacobellis A, Siciliano M, Perri F et al. PegIFN alfa-2b and RBV in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206-12.
91. Carrion JA, Martinez-Bauer E, Crespo G et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009; 50: 719-28.
92. Foruny JR, Blazquez J, Moreno A et al. Safe use of Peg-ylated IFN/RBV in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Eur J Gastroenterol Hepatol 2005; 17: 1157-64.
93. Miyake Y, Ando M, Kaji E et al. Partial splenic embolization prior to combination therapy of IFN and RBV in chronic hepatitis C patients with thrombocytopenia. Hepatol Res. 2008; 38: 980-6.
94. Morihara D, Kobayashi M, Ikeda K et al. Effectiveness of combination therapy of splenectomy and long-term IFN in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. Hepatol Res. 2009; 39: 439-47.
95. Ogata T, Kage M. Reconsidering splenectomy in cirrhosis. Changes and pros and cons. Acta Hepatologica Japonica 2010; 51: 205-18.
96. McHutchison JG, Dusheiko G, Shiffman ML et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-36.